智通财经APP讯，先声药业(02096)发布公告，于2025年12月7日，恩泽舒(注射用苏维西塔单抗)已被正 式纳入由国家医保局及人力资源社会保障部印发的《国家基本医疗保险、工伤保险和生育保险药品目录 (2025年)》，并将自2026年1月1日起生效。此外，恩度® (重组人血管内皮抑制素注射液)亦顺利完成国 家医保药品目录(NRDL)续约。 恩泽舒是新一代重组人源化抗血管内皮生长因子(VEGF)单克隆抗体，于2025年6月30日在中国获批上 市。恩泽舒联合紫杉醇、多柔比星脂质体或拓扑替康用于铂耐药后接受过不超过1种系统治疗的成人复 发性卵巢癌、输卵管癌或原发性腹膜癌的治疗。 恩度是中国第一个抗血管生成靶向药及全球唯一获准销售的内皮抑制素，自2017年起被纳入NRDL以 来，已成为晚期非小细胞肺癌治疗的基石用药之一。 ...

Core Viewpoint - The announcement by the company indicates that its drug, Enze Shu (Suvorexant injection), has been officially included in the National Medical Insurance Catalog for 2025, effective from January 1, 2026, which is a significant milestone for the company and its product offerings [1] Group 1: Drug Approvals and Listings - Enze Shu has been approved for the treatment of adult patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have received no more than one prior systemic therapy [1] - The drug was granted market approval in China on June 30, 2025, marking its entry into the market [1] - The company’s other drug, Endu (recombinant human vascular endothelial growth factor inhibitor injection), has successfully completed the renewal process for inclusion in the National Reimbursement Drug List (NRDL) [1] Group 2: Market Position and Significance - Enze Shu is a next-generation recombinant humanized monoclonal antibody targeting VEGF, which positions it as a novel treatment option in the oncology space [1] - Endu is recognized as China's first anti-angiogenesis targeted drug and the only endothelial inhibitor approved for sale globally, establishing it as a cornerstone treatment for advanced non-small cell lung cancer since its inclusion in the NRDL in 2017 [1]